PD9

(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide

Created:2015-10-30
Last modified:  2019-07-10

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count37
Chiral Atom Count0
Bond Count37
Aromatic Bond Count6
2D diagram of PD9
Toggle HydrogenToggle Labels

Chemical Component Summary

Name(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide
Systematic Name (OpenEye OEToolkits)(~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide
FormulaC14 H15 N3 O5
Molecular Weight305.286
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385CCN(CC)C(=O)C(=Cc1cc(O)c(O)c(c1)[N+]([O-])=O)C#N
SMILESOpenEye OEToolkits2.0.4CCN(CC)C(=O)C(=Cc1cc(c(c(c1)O)O)[N+](=O)[O-])C#N
Canonical SMILESCACTVS3.385 CCN(CC)C(=O)C(=C/c1cc(O)c(O)c(c1)[N+]([O-])=O)/C#N
Canonical SMILESOpenEye OEToolkits2.0.4 CCN(CC)C(=O)/C(=C/c1cc(c(c(c1)O)O)[N+](=O)[O-])/C#N
InChIInChI1.03 InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
InChIKeyInChI1.03 JRURYQJSLYLRLN-BJMVGYQFSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB00494 
NameEntacapone
Groups
  • approved
  • investigational
DescriptionEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. When administered concomittantly with levodopa and a decarboxylase inhibitor (e.g., carbidopa), increased and more sustained plasma levodopa concentrations are reached as compared to the administration of levodopa and a decarboxylase inhibitor.
Synonyms
  • Entacaponum
  • (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide
  • N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide
  • Entacapona
  • Entacapone
Brand Names
  • Corbilta
  • Entacapone
  • Comtan
  • Levodopa, Carbidopa and Entacapone Tablets
  • Carbidopa, Levodopa, and Entacapone
IndicationUsed as an adjunct to levodopa / carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off".
Categories
  • Anti-Dyskinesia Agents
  • Anti-Parkinson Drugs
  • Benzene Derivatives
  • Central Nervous System Agents
  • Central Nervous System Depressants
ATC-CodeN04BX02
CAS number130929-57-6

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Catechol O-methyltransferaseMPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLL...unknowninhibitor
Cytochrome P450 2D6MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVD...unknowninhibitor
Catechol O-methyltransferaseMPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLL...unknowninhibitor
UDP-glucuronosyltransferase 1A9MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...unknownsubstrate
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL953
PubChem 5281081
ChEMBL CHEMBL953
ChEBI CHEBI:4798